NANO-X IMAGING LTD's deep-learning medical imaging analytics subsidiary, Nanox AI Ltd, announced it will present new data from the AI-enabled Detection of Osteoporosis for Treatment (ADOPT) study at four major medical conferences through June 2025. The ADOPT study, which concluded in February 2025, evaluated HealthVCF at four UK National Health Services (NHS) trusts.
Earlier findings from the ADOPT study revealed that HealthVCF analyzed 37,220 routine medical CT scans and identified over 3,450 new patients with vertebral compression fractures, which is up to six times more than the national average at NHS hospitals in the UK. These patients were asymptomatic, underscoring the AI solution's ability to address a critical detection gap.
The presented data will also highlight the economic benefits of such AI tools, showing that AI-enabled Fracture Liaison Services, along with other improvements, led to a reduction in patient refracture rates of up to 10% and cost savings of up to £50,000 per healthcare organization over the study's duration. HealthOST, an upgraded and FDA-cleared version of the AI bone solution, features improved precision and the ability to highlight low bone mineral density in routine CT scans without additional radiation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.